Free radicals, antioxidant defense systems, and schizophrenia

The etiopathogenic mechanisms of schizophrenia are to date unknown, although several hypotheses have been suggested. Accumulating evidence suggests that excessive free radical production or oxidative stress may be involved in the pathophysiology of schizophrenia as evidenced by increased production of reactive oxygen or decreased antioxidant protection in schizophrenic patients. This review aims to summarize the basic molecular mechanisms of free radical metabolism, the impaired antioxidant defense system and membrane pathology in schizophrenia, their interrelationships with the characteristic clinical symptoms and the implications for antipsychotic treatments. In schizophrenia, there is accumulating evidence of altered antioxidant enzyme activities and increased levels of lipid peroxidation, as well as altered levels of plasma antioxidants. Moreover, free radical-mediated abnormalities may contribute to specific aspects of schizophrenic symptomatology and complications of its treatment with antipsychotic drugs, as well as the development of tardive dyskinesia (TD). Finally, the potential therapeutic strategies implicated by the accumulating data on oxidative stress mechanisms for the treatment of schizophrenia are discussed.

[1]  Takayuki Obata,et al.  Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study , 2008, PloS one.

[2]  M. Phillips,et al.  Increased pentane and carbon disulfide in the breath of patients with schizophrenia. , 1993, Journal of clinical pathology.

[3]  B. Harvey,et al.  Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: Reversal with olanzapine , 2003, Behavioural pharmacology.

[4]  L. Qi,et al.  The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients , 2009, Schizophrenia Research.

[5]  D. Sorescu,et al.  Modulation of Protein Kinase Activity and Gene Expression by Reactive Oxygen Species and Their Role in Vascular Physiology and Pathophysiology , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[6]  W. Carpenter The deficit syndrome. , 1994, The American journal of psychiatry.

[7]  J. Lieberman,et al.  Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[9]  S. Mukherjee,et al.  Enzymes of the antioxidant defense system in chronic schizophrenic patients , 1991, Biological Psychiatry.

[10]  F. Kapczinski,et al.  Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[11]  T. Shinkai,et al.  Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia: Relation to Tardive Dyskinesia , 2000, Neuropsychopharmacology.

[12]  Yan Shen,et al.  Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics , 2006, Schizophrenia Research.

[13]  D. Jeste,et al.  Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. , 1988, Schizophrenia bulletin.

[14]  J. Deleuze,et al.  Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  T. Kosten,et al.  Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. , 2007, The Journal of clinical psychiatry.

[16]  T. Woo,et al.  Oxidative stress in schizophrenia: An integrated approach , 2011, Neuroscience & Biobehavioral Reviews.

[17]  K. Uğurbil,et al.  Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.

[18]  G. Reynolds,et al.  Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment , 1993, International clinical psychopharmacology.

[19]  Vitamin E treatment of tardive dyskinesia. , 1993, The American journal of psychiatry.

[20]  K. Davies Oxidative stress: the paradox of aerobic life. , 1995, Biochemical Society symposium.

[21]  Alin Ciobica,et al.  Oxidative stress in schizophrenia - focusing on the main markers. , 2011, Psychiatria Danubina.

[22]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[23]  Matcheri Keshavan,et al.  Reduced plasma antioxidants in first-episode patients with schizophrenia , 2003, Schizophrenia Research.

[24]  P. Ranjekar,et al.  Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients , 2003, Psychiatry Research.

[25]  A. Kling,et al.  Glutathione peroxidase and CT scan abnormalities in schizophrenia , 1987, Biological Psychiatry.

[26]  Michael Berk,et al.  Medial temporal lobe glutathione concentration in first episode psychosis: A 1H-MRS investigation , 2009, Neurobiology of Disease.

[27]  Yong-Ku Kim,et al.  Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls , 2008, Schizophrenia Research.

[28]  B. Halliwell,et al.  Biochemistry of oxidative stress. , 2007, Biochemical Society transactions.

[29]  G. Meredith,et al.  Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats , 2003, Neuropharmacology.

[30]  A. Kling,et al.  Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: Relation to psychosocial variables , 1990, Psychiatry Research.

[31]  T. Kosten,et al.  Association of the manganese superoxide dismutase gene Ala–9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  R. Chan,et al.  Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. , 2011, The Journal of clinical psychiatry.

[33]  T. Lockwood,et al.  Redox control of protein degradation. , 2000, Antioxidants & redox signaling.

[34]  T. Kosten,et al.  Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[35]  D. Kammen,et al.  Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. , 1998, Journal of psychiatric research.

[36]  Jeffrey K. Yao,et al.  Reduced level of plasma antioxidant uric acid in schizophrenia , 1998, Psychiatry Research.

[37]  H. Herken,et al.  Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia , 2001, Molecular Psychiatry.

[38]  Abraham Nyska,et al.  Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification , 2002, Toxicologic pathology.

[39]  H. Lal,et al.  Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[40]  Brown Ja,et al.  Free radical involvement in neuropsychiatric illnesses. , 1995 .

[41]  X. Zhang,et al.  The Effect of Risperidone Treatment on Superoxide Dismutase in Schizophrenia , 2003, Journal of clinical psychopharmacology.

[42]  H. Holcomb,et al.  Phenotype of schizophrenia: a review and formulation , 2005, Molecular Psychiatry.

[43]  Bernhard Bogerts,et al.  The many faces of nitric oxide in schizophrenia. A review , 2005, Schizophrenia Research.

[44]  J. Castro-Fornieles,et al.  Reduced antioxidant defense in early onset first-episode psychosis: a case-control study , 2011, BMC psychiatry.

[45]  Ravinder Reddy,et al.  Altered Glutathione Redox State in Schizophrenia , 2005, Disease markers.

[46]  T. Shinkai,et al.  Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia , 2006, Psychiatry Research.

[47]  F. Tarazi,et al.  Long-term effects of newer antipsychotic drugs on neuronal nitric oxide synthase in rat brain. , 2002, Nitric oxide : biology and chemistry.

[48]  T. Kosten,et al.  Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[49]  E. Stadtman,et al.  Free radical-mediated oxidation of free amino acids and amino acid residues in proteins , 2003, Amino Acids.

[50]  P Boesiger,et al.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo , 2000, The European journal of neuroscience.

[51]  A. Kerkeni,et al.  Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients , 2011, BMC psychiatry.

[52]  R. Buzina,et al.  Vitamin C status in chronic schizophrenia , 1990, Biological Psychiatry.

[53]  G. Konat H2O2-induced higher order chromatin degradation: A novel mechanism of oxidative genotoxicity , 2003, Journal of Biosciences.

[54]  Etelvino J. H. Bechara,et al.  Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. , 1986, Clinical chemistry.

[55]  H. Herken,et al.  A Defect in the Antioxidant Defense System in Schizophrenia , 2009, Neuropsychobiology.

[56]  J. Lohr Oxygen radicals and neuropsychiatric illness. Some speculations. , 1991, Archives of general psychiatry.

[57]  Jun-Feng Wang,et al.  Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. , 2011, The international journal of neuropsychopharmacology.

[58]  V. Parikh,et al.  Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. , 2003, Journal of psychiatric research.

[59]  Elias S. J. Arnér,et al.  Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. , 2001, Free radical biology & medicine.

[60]  M. Egan,et al.  Treatment of tardive dyskinesia with vitamin E. , 1992, The American journal of psychiatry.

[61]  T. Kosten,et al.  Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia , 2012, Neuropharmacology.

[62]  B. Halliwell Phagocyte-derived reactive species: salvation or suicide? , 2006, Trends in biochemical sciences.

[63]  R. Reddy,et al.  Antioxidant therapeutics for schizophrenia. , 2011, Antioxidants & redox signaling.

[64]  Jeffrey K. Yao,et al.  Human plasma glutathione peroxidase and symptom severity in schizophrenia , 1999, Biological Psychiatry.

[65]  J. Smythies,et al.  Schizophrenia; a new approach. II. Result of a year's research. , 1954, The Journal of mental science.

[66]  R. McCreadie,et al.  The Nithsdale Schizophrenia Surveys. XIV: Plasma Lipid Peroxide and Serum Vitamin E Levels in Patients with and Without Tardive Dyskinesia, and in Normal Subjects , 1995, British Journal of Psychiatry.

[67]  J. Lohr,et al.  A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. , 1996, The Journal of clinical psychiatry.

[68]  I. Altuntaş,et al.  Erythrocyte Superoxide Dismutase and Glutathione Peroxidase Activities, and Malondialdehyde and Reduced Glutathione Levels in Schizophrenic Patients , 2000, Clinical chemistry and laboratory medicine.

[69]  Jeffrey K. Yao,et al.  Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. , 2011, Antioxidants & redox signaling.

[70]  A J Cross,et al.  Abnormal Involuntary Movements in Schizophrenia: Are They Related to the Disease Process or Its Treatment? Are They Associated with Changes in Dopamine Receptors? , 1982, Journal of clinical psychopharmacology.

[71]  S. Aust,et al.  Transition metals as catalysts of "autoxidation" reactions. , 1990, Free radical biology & medicine.

[72]  Jeffrey K. Yao,et al.  Reduced status of plasma total antioxidant capacity in schizophrenia , 1998, Schizophrenia Research.

[73]  V. Parikh,et al.  Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. , 2007, Journal of psychiatric research.

[74]  B. Olas,et al.  Isoprostenes as indicators of oxidative stress in schizophrenia , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[75]  T. Shinkai,et al.  No association between the Pro197Leu polymorphism in the glutathione peroxidase (GPX1) gene and schizophrenia , 2004, Psychiatric genetics.

[76]  W. Glazer,et al.  Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. , 1993, Archives of general psychiatry.

[77]  Young-Min Park,et al.  Manganese superoxide dismutase gene Ala–9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[78]  S. Mukherjee,et al.  Elevated Plasma Lipid Peroxides at the Onset of Nonaffective Psychosis , 1998, Biological Psychiatry.

[79]  A. Horton,et al.  Lipid peroxidation and mechanisms of toxicity. , 1987, Critical reviews in toxicology.

[80]  P. Lavori,et al.  Long-term treatment effects of vitamin E for tardive dyskinesia , 1998, Biological Psychiatry.

[81]  H. Canatan,et al.  Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder , 2002, Cell biochemistry and function.

[82]  X. Zhang,et al.  Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms , 2003, Psychiatry Research.

[83]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[84]  R. Reddy,et al.  Free radical pathology in schizophrenia: a review. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[85]  M. Keshavan,et al.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. , 2011, Antioxidants & redox signaling.

[86]  A. Ciobica,et al.  Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics , 2010, Neuroscience Letters.

[87]  Jeffrey K. Yao,et al.  Abnormal age-related changes of plasma antioxidant proteins in schizophrenia , 2000, Psychiatry Research.

[88]  H. Canatan,et al.  Association between Ala–9Val polymorphism of Mn-SOD gene and schizophrenia , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[89]  J. Coyle,et al.  Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. , 1998, The American journal of psychiatry.

[90]  A. Sarandol,et al.  Oxidative–antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[91]  Lin He,et al.  A meta-analysis of oxidative stress markers in schizophrenia , 2010, Science China Life Sciences.

[92]  D. Weinberger Implications of normal brain development for the pathogenesis of schizophrenia. , 1987, Archives of general psychiatry.

[93]  M. Berk,et al.  Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. , 2008, The international journal of neuropsychopharmacology.

[94]  S. Mukherjee,et al.  Impaired antioxidant defense at the onset of psychosis , 1996, Schizophrenia Research.

[95]  I. Grattagliano,et al.  An update on the role of free radicals and antioxidant defense in human disease , 1999, International journal of clinical & laboratory research.

[96]  D. Jeste,et al.  Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia , 1990, Biological Psychiatry.